Global Pharma and Biotech Summit 2027

The Global Pharma and Biotech Summit is the Financial Times' annual two-day London meeting for life sciences leaders, investors and policymakers. It covers growth, market access, AI, dealmaking and regulation.

Official site

Checked November 17, 2026

Reported attendance

350+

attendees · 2026

Reported exhibitors

Not published

How these are counted ↓

About Global Pharma and Biotech Summit 2027

The Global Pharma and Biotech Summit is the Financial Times' annual two-day conference for pharma and biotech leaders, investors and policymakers. FT Live says the next edition is coming in November 2027 in London, in person and online. It hasn't announced the 2027 dates or venue yet. The 2026 edition ran 10 to 11 November 2026 at Convene 22 Bishopsgate, and its page counts 350+ attendees and 260+ companies represented. It's a conference built around keynote interviews, panels and networking, not a trade show with stands.

Sources: pharma2025.live.ft.com, live.ft.com, pharma.live.ft.com

What happens at the Global Pharma and Biotech Summit

The summit is two days of FT-moderated CEO interviews, panel debates and networking on the business of medicines. FT Live's 2027 page sets out the themes for the next edition.

They're global competition and life sciences investment, pipeline renewal and dealmaking, and AI in drug development. Drug pricing, regulation and market access, and patients and trust, complete the list.

The 2026 agenda listed 42 sessions over 10 and 11 November 2026. Plenary sessions ran in the Bishopsgate Forum, the venue's main room. On the afternoon of day one the program split into two tracks.

The Business and Innovation Stage covered growth, dealmaking, science and operating models. The Policy, Patients and Public Health Stage covered regulation, pricing, patient pathways and health systems.

The FT says the 2026 sessions examined Europe’s competitiveness, US pricing after Most Favored Nation, AI, direct access to medicines, China and the NHS. FT and Endpoints News journalists moderated most sessions, and a reporters' roundtable closed the summit.

The 2026 sessions can be watched on demand through the agenda page. FT Live runs other London summits too, including the FT Future of AI Summit.

What's new for 2027

FT Live's 2027 page frames the next edition as competing for growth in a changing global market. Endpoints News stays on as collaboration partner.

The page lists AI's measurable results in drug development and pipeline renewal as themes. It also lists patients, trust and new models of care. Dates, venue, speakers and passes haven't been announced.

Who attends the Global Pharma and Biotech Summit

The audience is senior leaders from pharma, biotech, government, investment and the wider life sciences sector. FT Live's 2027 page cites 300+ in-person attendees, 66% at C-suite, MD or VP level, and 20 countries. It doesn't say which edition those figures describe.

The 2026 edition page counts 350+ attendees, 60+ speakers and FT journalists, 260+ companies represented and 20+ countries. It doesn't say whether the 350+ includes online attendees.

The organizer said 75% of in-person attendees in 2024 were CEO, managing director, VP or director level. Its 2025 page counted 300+ attendees, 45+ speakers, 320+ companies represented and 20+ countries.

For 2025, FT Live's who will you meet list named CEOs and board members of life sciences companies. It also named senior pharma and biotech function heads, CRO and supplier executives, and journalists.

Forvis Mazars, a 2025 sponsor, wrote that the 2025 summit brought together over 300 senior leaders. In 2026 the cheaper in-person pass was reserved for established pharmaceutical and biotech companies. Suppliers, advisers and service firms bought the Supplier Pass instead.

Attendance and exhibitors by year

As the organizer reports them. What's counted varies between events, so compare with care.

Reported attendance
300
350
20252026
EditionAttendance
2026

350+attendeesFrom the organizer's 2026 edition page after the event. It doesn't say whether online attendees are included.pharma.live.ft.com ↗

2025

300+attendeesFrom the organizer's 2025 edition site.pharma2025.live.ft.com ↗

Companies that sponsored and spoke at the Global Pharma and Biotech Summit

FT Live hasn't named sponsors for 2027 yet, apart from Endpoints News as collaboration partner on the 2027 page. The 2026 edition page named 13 sponsors and partners and five supporting partners.

Sponsors (14)AbbVie, Lonza, Roche and 11 more
Partners (13)Endpoints News, Endpoints News, McKinsey & Company and 10 more
Speakers' companies (28)Novartis, GSK, Novo Nordisk and 25 more

Drugmakers AbbVie, Roche, Boehringer Ingelheim, Merz Therapeutics, Santen and AtaiBeckley sponsored in 2026. Service firms McKinsey, Parexel, Lonza, PwC, Forvis Mazars and PA Consulting sponsored too.

Speakers' employers on the 2026 speaker list included Novartis, GSK, Novo Nordisk, Moderna, Takeda, Bayer, MSD and Gilead Sciences. Investors included J.P. Morgan, Jefferies, Novo Holdings, Sofinnova Partners, SV Health Investors, Medicxi and Royalty Pharma.

Regulators included the MHRA and the European Medicines Agency. A fuller 2026 company list of confirmed attendees sat behind a download form.

Exhibitors at the Global Pharma and Biotech Summit

The summit doesn't have exhibitors. The official site lists no exhibition, floor plan or stand packages. Companies take part as sponsors, speakers or delegates instead.

In 2026 suppliers to the industry attended on the Supplier Pass at £3,499 plus VAT. In-person attendees could use the FT Live networking app to find relevant attendees and arrange meetings. If you're planning meetings at a conference like this, compare event networking apps.

Sponsors and partners at the Global Pharma and Biotech Summit

FT Live sells sponsorship directly, and the 2027 page lists a sponsorship contact. It hasn't published 2027 sponsors beyond Endpoints News, the collaboration partner.

The 2026 edition page lists sponsors by tier. Endpoints News was the collaboration partner. McKinsey & Company was Global Knowledge Partner. Boehringer Ingelheim and Parexel were Strategic Partners.

AbbVie, Lonza and Roche were Lead Sponsors in 2026. AtaiBeckley, Forvis Mazars, Merz Therapeutics, PwC and Santen were Associate Sponsors. PA Consulting was Program Sponsor.

Supporting partners in 2026 were EUCOPE, the ABPI, The Pharma Letter, pharmaphorum and Pharmaceutical Technology. Forvis Mazars announced its 2026 Associate Sponsor role on its own newsroom.

Sponsorship usually came with speaking slots. Lonza's Matthew Moorcroft, PwC's Stephen Aherne and Santen's Marianthi Psaha were on the 2026 agenda.

The 2025 edition site listed sponsors including Medidata, ServiceNow, Ecolab, Kearney, Zühlke and Merz. There's no public prospectus. For running a sponsor program, see our event sponsorship software roundup.

The event's tech

We couldn't identify a third-party registration platform on the event's website.

Which platforms run B2B event registration →

Global Pharma and Biotech Summit attendee list, exhibitor list and sponsor list

FT Live doesn't publish an attendee list. For 2026 it offered a list of companies confirmed to attend as a download behind a contact form.

There's no exhibitor list because there's no exhibition. The 2026 sponsor list is the partner section of the 2026 edition page.

Registered delegates get the FT Live networking app. For 2025 the organizer said the app let users schedule meetings, explore the agenda and see the full attendee list. The online event community is open to Professional, Speaker, Sponsor and VIP ticket holders.

Be wary of anyone selling an attendee list. Our guide explains how to find who’s attending an event, and we compare event intelligence platforms.

See who's attending Global Pharma and Biotech Summit

Organizers don't publish attendee lists. These event intelligence platforms show which companies and roles are likely to attend and help you book meetings. How to find who's attending

Speakers at the Global Pharma and Biotech Summit 2027

The Global Pharma and Biotech Summit hasn't announced its 2027 speakers yet. The 2027 page gives a contact for speaking opportunities.

Global Pharma and Biotech Summit hasn't announced its 2027 speakers yet. Below is who spoke at past editions.

At the 2026 edition, the official agenda had keynote interviews with Moderna CEO Stéphane Bancel and Roche Pharmaceuticals CEO Teresa Graham. BioMarin CEO Alexander Hardy and Boehringer Ingelheim chairman Shashank Deshpande gave keynote interviews too.

Shreeram Aradhye of Novartis, Jérôme Bouyer of AbbVie, Katie Connelly of Parexel and Reinout Goedvolk of McKinsey also had keynote slots in 2026.

Regulators on the 2026 speaker list included MHRA chief executive Lawrence Tallon and Steffen Thirstrup, chief medical officer of the European Medicines Agency. Nathalie Moll of EFPIA and Richard Torbett of the ABPI represented industry bodies.

FT global pharmaceutical editor Hannah Kuchler and global health editor Sarah Neville moderated sessions in 2026. Endpoints News editors Drew Armstrong and Karen Weintraub moderated too.

Who spoke at Global Pharma and Biotech Summit 2026 (60)

  • Alexander Hardy, President and Chief Executive Officer, BioMarin
  • Jérôme Bouyer, President, International Therapeutics, AbbVie
  • Katie Connelly, Senior Vice President and Global Head of Regulatory Affairs, Parexel
  • Reinout Goedvolk, Global Life Sciences Practice Leader, McKinsey
  • Shashank Deshpande, Chairman of the Board of Managing Directors, Boehringer Ingelheim
  • Shreeram Aradhye, President, Development, and Chief Medical Officer, Novartis
  • Stéphane Bancel, CEO, Moderna
  • Teresa Graham, CEO, Roche Pharmaceuticals, Roche
  • Alex Devereson, Senior Partner, McKinsey
  • Alex Zhavoronkov, Founder and CEO, Insilico
  • Aliki Taylor, Executive Director of Epidemiology, Gilead Sciences
  • Anirban Sadhu, Vice President, Global Regulatory Affairs, Teva Pharmaceuticals
  • Bernhard Maier, Professor, King's College, London
  • Cui Cui, Managing Director and Head of Asia Healthcare, Jefferies
  • Earim Chaudry, Chief Medical Officer, Voy
  • Emily Pegg, Associate Vice President – Medical, Lilly UK & Northern Europe
  • Emma Warbey, Detective Inspector, Police Intellectual Property Crime Unit
  • Fiona Bride, Interim Director General for Commercial and Growth, NHS England and DHSC
  • Fiona du Monceau, EVP, Chief Commercial Officer, UCB Pharma
  • Giovanni Mariggi, co-founder and Partner, Medicxi
  • Greg Bailey, Co-founder and Executive Chairman, Juvenescence
  • Hong Chow, Executive Vice President, Product & Portfolio Strategy, Novo Nordisk
  • Hoyin Lam, Director Search & Evaluation – Oncology, R&D Business Development, GSK
  • Joanna Jenkinson, Director of Research and Development Policy, Association of the British Pharmaceutical Industry (ABPI)
  • Junaid Bajwa, Senior Partner, Head of UK, and Science Partner, Pioneering Intelligence
  • Kate Bingham, Managing Partner, SV Health Investors
  • Kenneth Sun, Head of Asia, Royalty Pharma
  • Kevin Craig, Chief Medical Officer, AtaiBeckley
  • Kim Branson, Chief AI Officer, GSK
  • Kris Naudts, Managing Partner, Firgun Ventures
  • Kultar Garcha, Chief Medical Officer of UK and EMEA, Hims & Hers
  • Laura Wallace, Global Head of Medical Evidence Generation, Takeda
  • Lawrence Tallon, Chief Executive Officer, Medicines and Healthcare Products Regulatory Agency
  • Louise Houson, Senior Vice President, MSD
  • Maina Bhaman, Partner, Sofinnova Partners
  • Marianthi Psaha, President EMEA, and Head of International Pricing, Market Access and Public Affairs, Santen
  • Mario Riesner, Head of Global Operations Human Pharma, Boehringer Ingelheim
  • Matthew Moorcroft, Chief Intelligence & Analytics Officer, Lonza
  • Mohammed Ali, Joint Managing Partner, NHS GP Pathfinders Clinics
  • Muriel O’Byrne, Senior Vice President, Head of International Regulatory Affairs and European Business Office, Regeneron Pharmaceuticals
  • Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings
  • Nichola Gokool, SVP, Head of Medical Communications, Parexel
  • Nigel Layton, Partner - Head of Pharma & Life Sciences, Forvis Mazars
  • Peter Wickersham, Vice President & GM - UK & Ireland, Gilead Sciences
  • Pushkal Garg, Chief R&D Officer and Executive Vice President, Alnylam Pharmaceuticals
  • Roy Wouters, Managing Director and Co-Head of EMEA Healthcare Investment Banking, J.P. Morgan
  • Sarah Sheikh, Head of the Neuroscience Therapeutic Area Unit, Takeda
  • Shane Degaris, Group Chief Executive Officer, Barts Health NHS Trust
  • Stefan König, CEO, Merz Therapeutics
  • Steffen Thirstrup, Chief Medical Officer, European Medicines Agency
  • Stephen Aherne, Pharma Partner, PwC
  • Tim Spector, Scientific Co-Founder, ZOE
  • Tina Vilsbøll, Senior Medical Officer, Novo Nordisk
  • Tomer Feffer, CEO UK & Ireland, Head of Region Northeast-Central Europe, Bayer
  • Venkat Sethuraman, SVP, Global Head of Data Science and Analytics, Roche
  • Amanda Lowe, Detective Chief Inspector and Head of the Police Intellectual Property Crime Unit (PIPCU), City of London Police
  • Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry
  • Hannah Kuchler, Global pharmaceutical editor, Financial Times
  • Sarah Neville, Global health editor, Financial Times

Dates, venue and getting there

The next summit is coming in November 2027 in London, in person and online. FT Live hasn't announced the exact dates or the venue yet.

The 2026 summit ran 10 to 11 November 2026 at Convene 22 Bishopsgate in the City of London. Registration and breakfast opened at 8 a.m. GMT on both days.

Convene says the venue spans nearly 38,000 square feet over two floors of 22 Bishopsgate. Its largest room holds up to 405 guests.

The 2025 edition also ran at Convene 22 Bishopsgate, on 11 to 12 November 2025.

Tickets and registration for the Global Pharma and Biotech Summit 2027

Passes for 2027 aren't on sale yet. The 2026 site links to a 2027 page with contacts for delegates, speakers and sponsors.

As a guide, the 2026 in-person Pharma and Biotech Pass cost £2,499 plus VAT at full price, checked in October 2026. It was for established pharma and biotech companies only, and FT Live could cancel bookings that didn't qualify.

The 2026 Supplier Pass cost £3,499 plus VAT. Both in-person passes included all sessions, networking and video on demand after the event.

Corporate packages saved 15% on three passes and 20% on five. The 2026 Digital Pass cost £479 plus VAT and covered sessions online, Q&A, polls and the networking app.

A video on-demand pass for the 2026 sessions costs £479 plus VAT for 90 days. The ABPI told its members they could save 20 percent on a 2026 in-person or digital pass.

FT Live also publishes a make the case to attend page with an email template for managers. Registration runs on FT Live's event site, built on Bizzabo.

History of the Global Pharma and Biotech Summit

The summit used to be called the FT Global Pharmaceutical and Biotechnology Conference. EFPIA's listing for the 2018 conference said it was then in its 36th year.

In 2014 the FT ran the conference in association with Deloitte, Consultancy.uk reported.

The 2025 edition ran under the theme Embracing an industry reset, in collaboration with Endpoints News. The 2026 theme was Rewriting the rules of growth, access and innovation.

FT Live, the FT's events division, also runs the FT Future of the Car Summit in London.

Frequently asked questions

When is Global Pharma and Biotech Summit 2027?
FT Live says it's coming in November 2027 in London. The exact dates and venue haven't been announced yet. The 2026 edition ran 10 to 11 November 2026.
Where is Global Pharma and Biotech Summit held?
It's held in London. The 2025 and 2026 editions ran at Convene 22 Bishopsgate in the City of London, and the 2027 venue isn't announced yet.
How many people attend Global Pharma and Biotech Summit?
FT Live's 2026 edition page counts 350+ attendees from 20+ countries. Its 2025 page listed 300+ attendees.
Who organizes Global Pharma and Biotech Summit?
The Financial Times presents it through FT Live, its events division. Endpoints News is the collaboration partner for 2027.
How much does a Global Pharma and Biotech Summit ticket cost?
2027 prices aren't published yet. In October 2026 the in-person Pharma and Biotech Pass cost £2,499 plus VAT, the Supplier Pass £3,499 and the Digital Pass £479.
Who attends the Global Pharma and Biotech Summit?
Senior leaders from pharma, biotech, government and investment attend. FT Live said 75% of 2024 in-person attendees were CEO, managing director, VP or director level.
Who sponsors the Global Pharma and Biotech Summit?
2027 sponsors aren't announced yet, apart from collaboration partner Endpoints News. In 2026 the edition page listed AbbVie, Lonza and Roche as Lead Sponsors and McKinsey & Company as Global Knowledge Partner.
Who is speaking at the Global Pharma and Biotech Summit 2027?
The 2027 speakers aren't announced yet. In 2026 the agenda had keynote interviews with Stéphane Bancel of Moderna, Teresa Graham of Roche and Alexander Hardy of BioMarin.
Is there an attendee list for the Global Pharma and Biotech Summit?
No public attendee list is published. For 2026 FT Live offered a list of companies confirmed to attend behind a download form, and delegates used the FT Live networking app.
Can suppliers attend the Global Pharma and Biotech Summit?
Yes. In 2026 suppliers bought the Supplier Pass at £3,499 plus VAT, because the Pharma and Biotech Pass was for established drug and biotech companies only.
Can you watch the Global Pharma and Biotech Summit online?
Yes. It runs in person and online, and the 2026 sessions are available through a video on-demand pass at £479 plus VAT.
Does the Global Pharma and Biotech Summit have exhibitors?
No. It's a conference without an exhibition, so companies take part as sponsors, speakers or delegates.